恩格列净对心力衰竭患者红细胞生成及铁动员机制的影响:EMPEROR项目
本研究在EMPEROR项目中纳入1,139例射血分数降低或保留的心力衰竭患者,检测基线、12周和52周血清铁代谢标志物。结果显示心力衰竭进展时红细胞生成素-红细胞铁酮-TfR1-铁调素轴激活,恩格列净进一步激活该轴并增加血红蛋白0.6-0.9 g/dL,同时降低铁调素和转铁蛋白饱和度。
要点
- 心力衰竭进展伴随红细胞生成素-红细胞铁酮-TfR1轴激活,预测心血管死亡或心衰住院风险升高。
- 恩格列净治疗12周增加血红蛋白0.6-0.9 g/dL,伴随红细胞铁酮升高>40%及铁利用增加。
- 基线铁缺乏患者恩格列净的红细胞生成反应减弱,但心力衰竭获益未减低。
核心结论
- 心力衰竭进展时红细胞生成素-红细胞铁酮-TfR1-铁调素轴激活,恩格列净进一步激活该轴并增强红细胞生成和铁动员利用。
研究设计与样本
- 在EMPEROR项目(EMPEROR-Reduced和EMPEROR-Preserved)中,纳入1,139例接受安慰剂或恩格列净治疗的心力衰竭患者。
- 在基线、12周和52周测量血清铁代谢标志物,分析其与临床状态及恩格列净对红细胞生成和心衰结局效应的关系。
主要发现
- 铁标志物间相关性提示存在功能性红细胞生成素-红细胞铁酮-转铁蛋白受体蛋白1(TfR1)-铁调素轴。
- 心力衰竭进展时红细胞生成素、红细胞铁酮和TfR1水平升高(P趋势<0.01),且这些蛋白水平预测心血管死亡或心衰住院风险升高(所有P<0.01)。
- 与安慰剂相比,恩格列净治疗12周使血红蛋白增加0.6至0.9 g/dL(P<0.001),伴随红细胞生成素-红细胞铁酮-TfR1轴进一步激活和铁利用增加。
- 恩格列净使血清红细胞铁酮水平升高>40%(同时红细胞生成素和TfR1升高),同时降低铁调素水平、血清铁浓度和转铁蛋白饱和度(所有P<0.01)。
- 基线铁缺乏患者接受恩格列净治疗时红细胞生成反应减弱(P趋势=0.04),但心力衰竭获益未减低。
临床怎么用
- 恩格列净通过激活红细胞生成素-红细胞铁酮-TfR1轴并抑制铁调素来增强红细胞生成和铁动员,这有助于理解其作用机制。
- 监测铁代谢标志物可能有助于评估恩格列净治疗反应,尤其基线铁缺乏患者红细胞生成反应可能减弱但心衰获益仍存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors stimulate erythropoiesis, but the mechanisms and clinical relevance of the effect of SGLT2 inhibitors on systemic iron metabolism in patients with heart failure is not well understood. OBJECTIVES: The authors sought to characterize a comprehensive suite of iron metabolism biomarkers-particularly the erythroblast signaling molecule, erythroferrone-in patients with heart failure before and after short- and long-term treatment with empagliflozin in patients with heart failure and a reduced or preserved ejection fraction. METHODS: We measured serum iron metabolism biomarkers at baseline, 12 weeks, and 52 weeks in 1,139 patients who were treated with placebo or empagliflozin in the EMPEROR (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure) program, and we characterized the inter-relationships of these biomarkers with clinical status and with the effect of empagliflozin on erythropoiesis and heart failure outcomes. RESULTS: Correlations among iron biomarkers indicated the presence of a functional erythropoietin-erythroferrone-transferrin-receptor-protein-1 (TfR1)-hepcidin axis. As heart failure advanced, patients showed higher levels of erythropoietin, erythroferrone, and TfR1 (P trend <0.01), and levels of these proteins predicted a heightened risk of cardiovascular death or heart failure hospitalization (all P < 0.01). Compared with placebo, at 12 weeks, empagliflozin increased hemoglobin by 0.6 to 0.9 g/dL (P < 0.001), an effect that was accompanied by further activation of the erythropoietin-erythroferrone-TfR1 axis and increased iron use. Empagliflozin increased serum levels of erythroferrone by >40% (along with increases in erythropoietin and TfR1), while simultaneously decreasing hepcidin levels and reducing serum iron concentrations and transferrin saturation (all P < 0.01). When treated with empagliflozin, patients with evidence of iron deficiency at baseline showed attenuation of the erythrocytic response (P trend = 0.04) but no diminution of the heart failure benefits. CONCLUSIONS: The erythropoietin-erythroferrone-TfR1-hepcidin axis is activated in patients with heart failure as the disease advances and is further heightened by SGLT2 inhibitors, in parallel with their effect to enhance erythropoiesis and iron mobilization and use. These changes have important implications for understanding the mechanism of action of SGLT2 inhibitors and for monitoring the response to treatment.
引用
- Ferreira, Anker, Butler, et al. Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR Program. J Am Coll Cardiol. 2025. PMID: 40335252. doi:10.1016/j.jacc.2025.03.503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。